COMPASS Pathways plc
NASDAQ:CMPSMedical - Care Facilities
+$0.02 today
- Market cap
- $1.15B
- Beta
- 2.51
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$1.63
Volume 2.35M
Average 4.09M
CMPS Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
COMPASS Pathways plcNASDAQ: CMPS
Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares grows, but more slowly than its trailing trend
Q1 FY2026 weighted avg shares of 110.06M shares rose 23.4% year over year, behind the +33.3% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 17.5% from the prior quarter. Over 3 fiscal years it compounded at +30.1% a year.
Context
- Weighted avg shares increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +23.4% toward the trailing-twelve-month pace of +33.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 93.5M USD
- Year-over-year change
- +38.6%
- 4-year CAGR
- +23.7%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 93.5M | +38.6% |
| FY2024 | 2024-12-31 | 67.48M | +32.2% |
| FY2023 | 2023-12-31 | 51.03M | +20.2% |
| FY2022 | 2022-12-31 | 42.44M | +6.1% |
| FY2021 | 2021-12-31 | 40M | — |
Weighted Avg Shares vs competitors
How CMPS compares with its peers on the latest reported figures
- CMPS's LTM Mar 2026 weighted avg shares of 98.1M shares is the 4th highest of the 11 companies compared; the peer median is 50.49M shares.
- Its year-over-year change of +33.3% is the 3rd highest of 10, against a peer median of +15.9%.
- Over three fiscal years its annual growth of +30.1% compares with a peer median of +14.2%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | 180.46M | +5.8% | +11.8% | |
| LTM Sep 2026 | 171M | +2.1% | +1.6% | |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | 111.19M | +30.7% | +42.5% |
| LTM Mar 2026 | 98.1M | +33.3% | +30.1% | |
| LTM Mar 2026 | 62.03M | +15.9% | +5.5% | |
| LTM Jun 2026 | 57.95M | +1.3% | -1.0% | |
| LTM Mar 2026 | 43.04M | +3.9% | +2.0% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | 41.9M | +115.2% | +32.7% |
| LTM Sep 2026 | 27.42M | +29.8% | +94.2% | |
| LTM Jun 2026 | 27.3M | +260.6% | +16.6% | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | 19.77M | — | +92.6% |
| Peer median (excluding CMPS) | 50.49M | +15.9% | +14.2% | |
Competitors are the stored peer set for CMPS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 44.03M | 65.05M | 87.52M | 119.04M | 118.44M |
| Selling, General & Admin | 39.19M | 45.35M | 49.4M | 59.17M | 60.6M |
| Operating Expenses | 83.22M | 110.4M | 136.92M | 178.21M | 179.04M |
| Depreciation & Amortization | 175K | 330K | 242K | 233K | 216K |
| EBITDA | (71.37M) | (90.77M) | (115.24M) | (148.82M) | (285.6M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (83.22M) | (110.4M) | (136.92M) | (178.21M) | (179.04M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 4.62M | 8.27M | 7.18M |
| Interest Expense | 0 | 0 | 2.2M | 4.48M | 4.52M |
| Other Income / Expenses | 11.68M | 19.31M | 19.24M | 24.68M | (111.3M) |
| Income Before Tax | (71.54M) | (91.1M) | (117.68M) | (153.53M) | (290.34M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 199K | 408K | 780K | 1.59M | (2.47M) |
| Net Income | (71.74M) | (91.51M) | (118.46M) | (155.12M) | (287.86M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.79) | (2.16) | (2.32) | (2.30) | (3.08) |
| EPS (Diluted) | (1.79) | (2.16) | (2.32) | (2.30) | (3.08) |
| Weighted Avg Shares | 40M | 42.44M | 51.03M | 67.48M | 93.5M |
| Weighted Avg Shares (Diluted) | 40M | 42.44M | 51.03M | 67.48M | 93.5M |
COMPASS Pathways plc
NASDAQ:CMPS
Intrinsic Alpha fair value
Locked
Current Price
$8.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.